ScoreWhy is Pyxis Oncology, Inc. ?
1
Negative results in Jun 25
- NET SALES(HY) At USD 2.82 MM has Grown at -82.53%
- NET PROFIT(HY) At USD -39.51 MM has Grown at -92.21%
- ROCE(HY) Lowest at -74.8%
2
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -34.73%, its profits have fallen by -28.5%
3
Below par performance in long term as well as near term
- Along with generating -34.73% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Pyxis Oncology, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Pyxis Oncology, Inc.
1.99%
-0.66
109.46%
S&P 500
13.99%
0.81
19.85%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
30.19%
EBIT Growth (5y)
-342.88%
EBIT to Interest (avg)
-65.66
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.02
Sales to Capital Employed (avg)
0.08
Tax Ratio
2.22%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
67.57%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.81
EV to EBIT
0.25
EV to EBITDA
0.26
EV to Capital Employed
9.49
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
3742.04%
ROE (Latest)
-72.03%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend4What is working for the Company
NET PROFIT(HY)
Higher at USD -39.51 MM
RAW MATERIAL COST(Y)
Fallen by -8,103% (YoY
-18What is not working for the Company
NET SALES(HY)
At USD 2.82 MM has Grown at -82.53%
NET PROFIT(HY)
At USD -39.51 MM has Grown at -92.21%
ROCE(HY)
Lowest at -74.8%
Here's what is working for Pyxis Oncology, Inc.
Net Profit
Higher at USD -39.51 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Raw Material Cost
Fallen by -8,103% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Pyxis Oncology, Inc.
Net Sales
At USD 2.82 MM has Grown at -82.53%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (USD MM)
Net Profit
At USD -39.51 MM has Grown at -92.21%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
